ImetelChat

Interesting post: Repost from YMB Sdrawkcabeman Although Imerge's P3 was always designed as a double-blind, yesterday's update now indicates: "masked role: participant, investigator." It's either a detail they're just now getting around to updating, or they're putting a polish on it in prep for the ...

Looks like preparation for Phase 3.

The 12 September Geron PR says about the 9.4: '../.. this arm warrants further investigation because encouraging trends in the efficacy data were observed'. 'Efficacy' means they saw the drug actually improve certain elements of the disease. We can only guess what they exactly saw, because nothing w...

rob, thanks for the notice. But this was already uploaded to the imetelstat.info site on 23 February.

rob: can you re-post his post here?

Do you mean this article: http://www.nature.com/cdd/journal/v12/n ... 1670a.html
Sometimes it gives an internal server error. Maybe if you try a couple of times. With me it worked in the end.

Thanks, Hunt. Maybe I was confronting a bit too much, as that also brings the quality down. Btw: on SA quite some posts were deleted lately, also some of mine (which was fully justified...). So they do at least something, which can't be said from the YMB. Relevant posts on SA or YHM certainly should...

Thanks for your advice, Bio.

Hi Hip, I appreciate your advice. I try to respond less, but sometimes I just can't bare to see how just a couple of people are deliberately distorting such high quality board. Maybe I should follow your advice and ignore them completely. When data come out (or other kind of news) the real discussio...

Great post from CKTC. Thanks for sharing it here, HOOSIER.

I don't see a direct link with GERN. It is not even said that the will actually sell those shares, just that they may. There is no timing connected, so we don't know how and when they will sell, if at all.

Hi rob, I don't think an AML trial will be anmnounced before Q2 review. This is for two reasons: JnJ wnats to include all data of the current trials (IMbark, IMegre, Mayo Pilot) to be included into the decission making of any AML trial, especially regarding dosing (see email Anna). Secondly, my gues...

This is the link: http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11924971&RcvdDate=3/10/2017&CoName=INCYTE%20CORP&FormType=424B7&View=html BB seems to sell their INCY position. They may want to benefit from the merger rumor. At the same time it may be a sign that they are not confident in ...

Sargasso, thanks for these relevant questions. Scarlett indeed announced some time ago that JnJ (not Geron!) was going to present the results of Imbark, IMerge and all other data from the full imetelstat program to a regulatory authority (FDA, EMA,...). Btw: this is not about submission for approval...

bio, I believe you were not impressed by this article. Why is that? The suppressing of fibrogenic growth factors sounds pretty relevant, as it is a very nasty feature of the disease. It also a kind of confirms that imetelstat may reverse fibrosis or prevent it from occurring in the first place. Or a...

Bio, thanks for posting. Here the full abstract: Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. "Imetelstat (GRN163L) is a specific telomerase inhibitor which has demonstrated clinical activity in patients with myeloproliferative neoplasms (MPN) and...

Some have got a bit depressed indeed, although I think the venetoclax paper was fairly valued as being positive. Off course there were questions regarding how long it would take before such trials would start, and if they could start before imetelstat would be approved as a single drug. Maybe JnJ ha...

SA has some great posters. It is interesting to see how negativity takes its turn just when real exciting things may happen on the short term (Q2). Let's stay focussed on the facts and information we can find. Critical discussions are important, as long we use arguments. Let's make sure we can proce...

Bio, good question. But the answer is no. I haven't seen any updates/details on that. Indeed it would be VERY interesting to know given the LE of 7 months for the R/R patients.

Nice post from sdrawkcabeman (YHMB): "Things are coming to a head in a few short months. It's taken a rather circuitous path to get here, between the 2014 hold and its release, the silence on the AML front, and the unexpected 2016 review. But we are finally here. In hindsight, IMbark's focus on R/R ...